A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder
Status:
Terminated
Trial end date:
2019-06-21
Target enrollment:
Participant gender:
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of
Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who
are at imminent risk of suicide.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan Naurex, Inc, an affiliate of Allergan plc